bioRxiv · 10.1101/189324
SCGN Administration prevents Insulin Resistance and Diabetic Complications in High-Fat Diet Fed Animals
Abstract
Secretagogin (SCGN) is poorly-studied secretory/cytosolic CaBP enriched in pancreatic {beta}-cells. Recent studies implicated SCGN in diabetes; however, its function and therapeutic prospect remain uncharted. Based on the apparent synchrony of SCGN and insulin secretion (and its disruption in HFD-fed animals) and considering SCGN downregulation in Type 2 diabetes, we hypothesized that SCGN is a key regulator of insulin response. To test this, we administered rSCGN to HFD-fed animals. We here report that a novel SCGN-insulin interaction stabilizes insulin and potentiates insulin action. Moreover, a chronic rSCGN administration improves insulin response and alleviates obesity associated risk factors such as weight gain, liver steatosis and cholesterol imbalance in DIO animals. Beside the anti-diabetic effects, prolonged rSCGN treatment also induces {beta}-cell regeneration. These effects seem to originate from SCGN mediated regulation of insulin concentration & function as validated in insulin-deficient STZ animals. Our results demonstrate the prospects of the therapeutic potential of SCGN against diabetes.
Source connections
Explore related subjects
Keep this discovery
Sharma, A. K., Khandelwal, R., Chadalawada, S., Ram, N. S., Raj, A., Mahesh Kumar, J., Sharma, Y.. 2017-09-15. SCGN Administration prevents Insulin Resistance and Diabetic Complications in High-Fat Diet Fed Animals. https://doi.org/10.1101/189324
Cite the original work for its findings. Save a collection to share your selection of sources.